Roche wins FDA approval for Wilserdly in ESR1-mutated advanced breast cancer

Key highlights
  • Wilserdly (giredestrant) plus everolimus is approved for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after endocrine therapy.
  • In phase III evERA, the combination reduced the risk of disease progression or death by 62% versus standard endocrine therapy plus everolimus (HR 0.38).
  • ESR1 mutations, a cause of endocrine therapy resistance, affect up to 40% of patients with HR-positive metastatic breast cancer.
  • The FDA is reviewing Wilserdly for adjuvant use, with a decision expected by 30 November 2026.

FDA approval

The FDA approved Roche’s Wilserdly (giredestrant) with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The indication covers disease recurring during or after endocrine-based adjuvant therapy, or progressing on at least one endocrine-based regimen in the metastatic setting. ESR1 mutations are reported in up to 40% of patients with HR-positive metastatic breast cancer and are associated with resistance to hormone therapy.

Phase III evidence

Approval was supported by the evERA study in patients whose disease had progressed after CDK4/6 inhibitor therapy. The combination significantly prolonged progression-free survival, reducing the risk of progression or death by 62% versus standard endocrine therapy plus everolimus (hazard ratio 0.38; 95% confidence interval 0.27–0.54; p<0.0001). Both medicines are taken orally.

Adjuvant application

The FDA is also reviewing Wilserdly as adjuvant treatment for adults with ER-positive, HER2-negative stage I–III breast cancer at intermediate to high risk of recurrence. The application, based on the phase III lidERA study, received Priority Review. The FDA’s decision date is 30 November 2026.

Source: Roche

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

18 October 2026
Genentech unveils late‑stage oncology data at ESMO 2026

Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.

30 September 2026
Genentech: Giredestrant + everolimus improves PFS in ER‑positive advanced breast cancer (evERA Phase III, NEJM)

evERA Phase III: giredestrant+everolimus doubled median PFS in ESR1‑mutated patients and improved ITT PFS; OS immature; manageable safety; FDA review dates set for Nov 30 and Dec 18, 2026.

2 June 2026
Roche: FDA accepts priority‑review NDA for giredestrant in ER‑positive early‑stage breast cancer

FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.

1 June 2026
Genentech: FDA accepts NDA for giredestrant after positive Phase III adjuvant results in early ER‑positive breast cancer

lidERA Phase III: giredestrant reduced invasive recurrence/death by 30% (HR 0.70); 3‑yr iDFS 92.4% vs 89.6%. Priority review; PDUFA Nov 30, 2026; well tolerated in >4,100 pts.

22 October 2026
Roche: Group sales +6% (CER) YTD; Q3 +7% (CER) and +8% in CHF

Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.